<DOC>
	<DOCNO>NCT02791815</DOCNO>
	<brief_summary>The primary purpose study evaluate effect repeat dos selexipag pharmacokinetics single oral dose midazolam ( i.e. , long much midazolam present blood )</brief_summary>
	<brief_title>Potential Pharmacokinetic Interaction Between Selexipag Midazolam Healthy Male Subjects</brief_title>
	<detailed_description>In order exclude inductive effect selexipag gastrointestinal tract , study aim investigate effect selexipag PK midazolam , sensitive substrate hepatic intestinal cytochrome P450 3A4 ( CYP3A4 ) .</detailed_description>
	<mesh_term>Selexipag</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Key Signed informed consent form Age 18 45 year ( inclusive ) screen Body mass index ( BMI ) 18.0 28.0 kg/m2 ( inclusive ) screen Healthy basis physical examination , cardiovascular assessment laboratory test Key Any contraindication study treatment History clinical evidence disease medical / surgical condition treatment , may put subject risk participation study may interfere absorption , distribution , metabolism excretion study treatment Any circumstance condition , , opinion investigator , may affect subject 's full participation study compliance protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>selexipag</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>midazolam</keyword>
</DOC>